Deuschle M, Blum W F, Frystyk J, Orskov H, Schweiger U, Weber B, Körner A, Gotthardt U, Schmider J, Standhardt H, Heuser I
Max Planck Institute of Psychiatry, Clinical Institute, München, Germany.
Int J Sports Med. 1998 May;19(4):250-4. doi: 10.1055/s-2007-971913.
There is an age-associated decline in the activity of the GH-IGFs system. However, so far, it has not been studied, whether this decline in somatotrophic activity might be preventable by intensive exercising. We studied 11 elderly male (50-78 years) marathon runners and 10 age-matched male (52-73 years) sedentary controls to evaluate plasma concentrations of GH, total and free IGF-I and IGF-II and of IGF-binding protein-1 (IGFBP-1), IGFBP-2, IGFBP-3 and insulin. When comparing the two groups (runners vs controls) no differences were found in GH (1.0 +/- 1.2 vs 1.3 +/- 1.3 microg/l [mean +/- SD]), IGF-1 (115 +/- 23 vs 113 +/- 21 microg/l), IGF-II (961 +/- 192 vs 864 +/- 125 microg/l), free IGF-1 (227 +/- 80 vs 318 +/- 146 ng/l), free IGF-II (563 +/- 249 vs 492 +/- 108 ng/l), IGFBP-3 (2403 +/- 515 vs 2307 +/- 326 microg/l) or insulin (26 +/- 13 vs 27 +/- 18 mU/l). However, IGFBP-1 (4.44 +/- 2.61 vs 2.28 +/- 0.93 microg/l) and IGFBP-2 (493 +/- 143 vs 340 +/- 186 microg/l) were found to be significantly increased in marathon runners. In conclusion, our findings do not support the hypothesis that the age-associated decline in GH, IGF-1 and IGFBP-3 may be preventable by intensive endurance training. However, marathon running affects the regulation of the GH-IGFs system activity at the level of IGFBP-1 and -BP-2.
生长激素-胰岛素样生长因子（GH-IGFs）系统的活性会随着年龄的增长而下降。然而，迄今为止，尚未研究过这种生长激素活性的下降是否可以通过高强度运动来预防。我们研究了11名老年男性（50 - 78岁）马拉松运动员和10名年龄匹配的男性（52 - 73岁）久坐不动的对照者，以评估血浆中生长激素、总胰岛素样生长因子-I（IGF-I）、游离IGF-I、IGF-II以及胰岛素样生长因子结合蛋白-1（IGFBP-1）、IGFBP-2、IGFBP-3和胰岛素的浓度。比较两组（跑步者与对照组）时，发现生长激素（1.0±1.2 vs 1.3±1.3微克/升[平均值±标准差]）、IGF-1（115±23 vs 113±21微克/升）、IGF-II（961±192 vs 864±125微克/升）、游离IGF-1（227±80 vs 318±146纳克/升）、游离IGF-II（563±249 vs 492±108纳克/升）、IGFBP-3（2403±515 vs 2307±326微克/升）或胰岛素（26±13 vs 27±18毫单位/升）没有差异。然而，发现马拉松运动员的IGFBP-1（4.44±2.61 vs 2.28±0.93微克/升）和IGFBP-2（493±143 vs 340±186微克/升）显著升高。总之，我们的研究结果不支持通过高强度耐力训练可以预防与年龄相关的生长激素、IGF-1和IGFBP-3下降的假设。然而，马拉松跑步会在IGFBP-1和-BP-2水平上影响GH-IGFs系统活性的调节。
